Akeso (09926): AstraZeneca’s US$2bn Summit investment strengthens J.P. Morgan’s positive view of Akeso’s ivonescimab

Overview

This event commentary assesses what AstraZeneca’s US$2bn strategic investment in Summit Therapeutics means for Akeso, the developer of ivonescimab. J.P. Morgan argues that the deal provides a positive read-through for Akeso by validating the asset’s strategic value and improving support for its global development pathway, while important regulatory and late-stage trial catalysts remain ahead.

Core views

J.P. Morgan views AstraZeneca’s US$2bn strategic equity investment in Summit Therapeutics, alongside a clinical collaboration, as a clear external validation event for ivonescimab, the PD-1/VEGF bispecific antibody developed by Akeso and licensed to Summit for development outside China. The investment is structured as convertible preferred shares at US$18.36 per common-share equivalent, a premium of 18.6% to Summit’s 28 September close. It is expected to amount to roughly 12% of Summit’s outstanding common stock, or just under 11% on a fully diluted basis. The institution considers the transaction a meaningful endorsement by a major global oncology participant, particularly because AstraZeneca had reportedly explored a licensing partnership with Summit around the asset in 2025. The timing is central to the report’s thesis. AstraZeneca is investing before potentially high-risk milestones: the 14 November PDUFA date for ivonescimab in second-line or later EGFR-positive NSCLC, and final Phase 3 PFS data from the HARMONi-3 squamous NSCLC cohort expected in 4Q26. J.P. Morgan interprets the decision to invest before these outcomes as evidence of AstraZeneca’s confidence in ivonescimab and its broader immuno-oncology combination potential. It therefore raises J.P. Morgan’s assessment of the probability of success for US approval and positive HARMONi-3 readouts, while noting that either catalyst could still create negative headline risk. The collaboration is intended to pair ivonescimab with AstraZeneca ADC assets, including the CLDN18.2 ADC Sone-Ve in first-line gastric cancer. J.P. Morgan believes this could expand the asset’s opportunity beyond monotherapy and standard immuno-oncology/chemotherapy combinations, including gastrointestinal cancers. The report argues that the US$2bn capital injection also gives Summit resources to pursue more ex-China Phase 3 studies, potentially accelerating and broadening the global strategy. Although Summit has other clinical collaboration agreements with GSK, Revolutionary Medicine and Arcus, J.P. Morgan highlights AstraZeneca as the first partner to make a significant equity investment; further evidence of a deeper AZN/Summit clinical collaboration would be positive for Akeso. For Akeso, the institution sees stronger global development momentum as supportive of its retained China franchise, royalty and milestone economics, and investor perception of ivonescimab. Separately, its longer-term investment case rests on expansion of AK104 in China, for which it forecasts about Rmb7bn peak China sales, and AK112’s expected NRDL inclusion and China sales momentum, also with more than Rmb7bn peak China sales. J.P. Morgan further expects AK112’s efficacy profile and position in PD-(L)1/VEGF to support ex-China peak sales of more than US$5bn. The report retains Overweight and a Dec-2027 price target of HK$125. Its DCF estimates Akeso free cash flow through 2034, using a 9.6% WACC and a 3.0% terminal growth rate. The valuation shows total equity value of Rmb104,075mn, including Rmb3,288mn for Summit equity value, and derives a per-share value of HK$125.

Analysis framework

J.P. Morgan first interprets the investment’s structure, scale and timing as evidence of AstraZeneca’s confidence in ivonescimab. It then traces the implications for Summit’s ability to fund ex-China trials and for Akeso’s China franchise, royalty and milestone exposure. Finally, it frames the pending clinical and regulatory milestones against a DCF-based target price for Akeso.

Methodology notes

• Valuation methodsDCF (Discounted Cash Flow)

  Discounted cash flow valuation

  J.P. Morgan forecasts Akeso’s free cash flow through 2034, discounts it using a 9.6% WACC, and applies a 3.0% terminal growth rate to derive its HK$125 per-share target value.

• Event-Driven and Behavioral FinanceEvent-driven analysis

  Event-driven analysis of AstraZeneca’s investment and collaboration

  The report treats AstraZeneca’s investment before key regulatory and trial readouts as a signal about the perceived strategic value and probability of success of ivonescimab.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Akeso (9926.HK)

  Primary covered company and developer of ivonescimab, licensed to Summit for development outside China.

  Strengths

  AstraZeneca’s investment is viewed as validation of ivonescimab; Akeso retains China-franchise, royalty and milestone exposure. AK104 and AK112 are expected to be major growth drivers.

  Comparison

  The report cites AK112’s highly competitive efficacy profile versus Keytruda.

  Risks

  Pipeline development setbacks and AK104 or AK112 sales below J.P. Morgan expectations.

• Summit Therapeutics (SMMT)

  Ex-China licensee and development partner for ivonescimab; recipient of AstraZeneca’s strategic investment.

  Strengths

  The investment provides additional capital and resources for ex-China Phase 3 trials and combination studies with AstraZeneca’s ADC portfolio.

  Weaknesses

  Key regulatory and Phase 3 catalysts could create negative headline risk.

  Comparison

  AstraZeneca is the first of Summit’s collaborators to make a significant equity investment.

  Risks

  Potential negative outcomes from the 14 November PDUFA decision or HARMONi-3 final PFS data.

Key data

• AstraZeneca investment in SummitUS$2bnStrategic equity investment accompanied by a clinical collaboration around ivonescimab.
• Convertible preferred-share priceUS$18.36 per common-share equivalentRepresents an 18.6% premium to Summit’s 28 September close.
• AstraZeneca ownership on conversionAbout 12% outstanding common stock; just under 11% fully dilutedExpected ownership from the investment.
• HARMONi-GI1 expected overall-survival hazard ratio≤0.6J.P. Morgan’s expectation for data to be featured at the ESMO’26 Presidential Symposium II on 25 October; Akeso had disclosed the trial met its primary OS endpoint.
• Akeso price targetHK$125.00Dec-2027 target based on DCF valuation.
• DCF assumptions9.6% WACC; 3.0% terminal growth rateFree cash flow is estimated through 2034.
• AK104 China peak-sales estimate~Rmb7bnLinked to expansion into large China-market indications.
• AK112 sales estimates>Rmb7bn China peak sales; US$5bn+ ex-China peak salesThe China outlook assumes successful NRDL inclusion; ex-China potential reflects the PD-(L)1/VEGF opportunity and efficacy profile.

Impact & implications

J.P. Morgan believes the deal improves the strategic and financial support behind ivonescimab’s ex-China development and reinforces its potential across additional combination settings. For Akeso, this is viewed as supportive of its China franchise, royalty and milestone economics, and investor perception, while forthcoming data and approval decisions remain material determinants of the thesis.

Risks

• Pipeline development setbacks could undermine the rating and price target.
• AK104 or AK112 sales could fall below J.P. Morgan’s expectations.
• The 14 November PDUFA decision and HARMONi-3 final PFS data could create negative headline risk for Summit and ivonescimab.

What to watch

• Details of the AZN/Summit combination-trial design, including potential pairing of ivonescimab with Sone-Ve in first-line gastric cancer and broader ADC combinations.
• HARMONi-GI1 Phase 3 biliary tract cancer data at the ESMO’26 Presidential Symposium II on 25 October.
• The 14 November PDUFA date for second-line or later EGFR-positive NSCLC.
• Final Phase 3 PFS data from the HARMONi-3 squamous NSCLC cohort in 4Q26.
• Any further AZN/Summit news indicating a deeper clinical collaboration.